Ken Bartizal, Chief Development Officer at Trius Therapeutics Inc (TSRX), sold 12,000 shares at $7.85 ($94K) on 2013-05-14, disclosed to the SEC on 2013-05-28.
Open-market sale of $94k TSRX by Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| TSRX | SELL | 2013-05-28 | $95K | — | Filing → |
| TSRX | SELL | 2011-11-18 | $13K | — | Filing → |